Companies /Healthcare

Nurix Therapeutics Inc

NASDAQ: NRIX Biotechnology
$26.72
▼ $0.23 (−0.85%) today
Markets open · 3:26pm ET

Q3 2025 Earnings

Reported Oct 9, 2025, 4:02pm ET · SEC source
$-1.03
Miss −21.08%
EPS · est. $-0.85
$7.9M
Miss −50.85%
Revenue · est. $16.1M
+27.2%
Beating market
NRIX vs S&P since report
2 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
0+4%+8%Oct 9Oct 10report 4:02pm ETearnings−2.7%−1.4%
0+4%+8%Oct 9Oct 10earnings−2.7%−1.4%
NRIX −1.4%S&P 500 −2.7%
−4%0+4%+8%Oct 9Oct 10report 4:02pm ETearnings−3.5%−1.4%
−4%0+4%+8%Oct 9Oct 10earnings−3.5%−1.4%
NRIX −1.4%NASDAQ −3.5%
−10%−5%0+5%Oct 8Oct 17report 4:02pm ETearnings−1.0%−3.6%
−10%−5%0+5%Oct 8Oct 17earnings−1.0%−3.6%
NRIX −3.6%S&P 500 −1.0%
−10%−5%0+5%Oct 8Oct 17report 4:02pm ETearnings−1.1%−3.6%
−10%−5%0+5%Oct 8Oct 17earnings−1.1%−3.6%
NRIX −3.6%NASDAQ −1.1%
−10.13%
Day of report
−0.41%
Next session
+0.82%
One week
+31.76%
30 days

S&P 500 over the same 30 days: +4.59%.

Did NRIX Beat Earnings? Q3 2025 Results

Nurix Therapeutics delivered a sharply disappointing fiscal third quarter, missing on both the top and bottom lines as the clinical-stage biotech ramped spending ahead of pivotal trials for its lead drug candidate bexobrutideg. Revenue fell 37.3% year over year to $7.89 million, well short of the $16.06 million consensus and reflecting a 50.85% miss, as collaboration income from Sanofi declined following the end of an initial research term for certain drug targets. The wider-than-expected net loss drove earnings per share to a loss of $1.03, missing the $-0.85 consensus estimate by 21.08%, with R&D expenses surging to $86.12 million from $55.48 million a year ago as the company accelerated clinical enrollment and manufacturing tied to bexobrutideg. Analysts subsequently trimmed price targets, though buy-side sentiment remained broadly constructive given the drug's 80.9% overall response rate in relapsed and refractory CLL patients. Nurix closed the quarter with $428.83 million in cash and marketable securities and plans to initiate pivotal CLL trials in the second half of 2025.

Key Takeaways
  • Accelerated enrollment and clinical trial expansion for bexobrutideg driving increased R&D spend
  • Lower Sanofi collaboration revenue as initial research term for certain drug targets ended
  • Higher percentage of completion of Pfizer collaboration performance obligations partially offset revenue decline

“Nurix is preparing to initiate pivotal studies for bexobrutideg in relapsed/refractory CLL patients in the fourth quarter of 2025 and we have outlined our plans for potential accelerated approval with a single arm study as well as a confirmatory randomized control Phase 3 study for full approval.”

Nurix Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

Nurix plans to initiate pivotal trials for bexobrutideg in relapsed/refractory CLL in H2 2025, including a single-arm study for potential accelerated approval and a randomized controlled Phase 3 trial for full approval. The company is also enrolling a Phase 1b cohort for bexobrutideg in CLL patients with autoimmune hemolytic anemia and conducting Phase 1 healthy volunteer studies to support a potential autoimmune IND filing in 2026. Additional clinical, preclinical, and program updates are expected throughout 2025 at major medical conferences including ESMO, SITC, and ASH. Nurix expects to continue achieving substantial research collaboration milestones across its partnerships with Gilead, Sanofi, and Pfizer.

NRIX YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$-400,000,000$-200,000,000$0$12.6M$7.9MRevenue$-279,807,103$-91,385,000Operating Income$-368,219,003$-86,421,000Net Income
$-400,000,000$-200,000,000$0RevenueOperating IncomeNet Income

NRIX Revenue by Segment

License Revenue
Collaboration Revenue$7.9M

Figures from SEC filings and company reports. Not investment advice.